Indivior Pharmaceuticals, Inc. (INDV)
32.45
-1.17
(-3.48%)
USD |
NASDAQ |
Oct 16, 16:00
32.41
-0.04
(-0.12%)
After-Hours: 20:00
Indivior Pharmaceuticals Free Cash Flow (Quarterly) : 221.58M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 221.58M |
| March 31, 2026 | -29.00M |
| December 31, 2025 | -249.85M |
| September 30, 2025 | -62.24M |
| June 30, 2025 | 147.23M |
| March 31, 2025 | 70.00M |
| December 31, 2024 | -33.68M |
| September 30, 2024 | -4.199M |
| June 30, 2024 | 82.90M |
| March 31, 2024 | -40.00M |
| December 31, 2023 | -298.31M |
| September 30, 2023 | -6.725M |
| June 30, 2023 | -19.67M |
| March 31, 2023 | -42.00M |
| December 31, 2022 | -18.83M |
| September 30, 2022 | 54.67M |
| June 30, 2022 | 21.77M |
| March 31, 2022 | -75.00M |
| December 31, 2021 | 162.27M |
| September 30, 2021 | 25.71M |
| June 30, 2021 | 39.64M |
| March 31, 2021 | 89.00M |
| December 31, 2020 | -74.32M |
| Date | Value |
|---|---|
| September 30, 2020 | 26.08M |
| June 30, 2020 | -4.046M |
| March 31, 2020 | -146.00M |
| December 31, 2019 | 35.95M |
| September 30, 2019 | 37.99M |
| June 30, 2019 | -61.71M |
| March 31, 2019 | 133.00M |
| December 31, 2018 | 83.03M |
| September 30, 2018 | 100.87M |
| June 30, 2018 | 56.56M |
| March 31, 2018 | 18.00M |
| December 31, 2017 | 56.33M |
| September 30, 2017 | 24.90M |
| June 30, 2017 | 118.08M |
| March 31, 2017 | 52.00M |
| December 31, 2016 | 129.00M |
| September 30, 2016 | 101.42M |
| June 30, 2016 | 76.75M |
| March 31, 2016 | 93.00M |
| December 31, 2015 | 36.32M |
| September 30, 2015 | 47.80M |
| June 30, 2015 | 40.95M |
| March 31, 2015 | 165.00M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Supernus Pharmaceuticals, Inc. | -5.378M |
| Eli Lilly & Co. | 4.475B |
| Bristol Myers Squibb Co. | 3.088B |
| Liquidia Corp. | 69.01M |
| Harmony Biosciences Holdings, Inc. | 92.43M |